Misplaced Pages

:WikiProject Chemicals/Chembox validation/VerifiedDataSandbox and Androstenediol: Difference between pages - Misplaced Pages

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
(Difference between pages)
Page 1
Page 2
Content deleted Content addedVisualWikitext
Revision as of 18:27, 16 February 2012 editBeetstra (talk | contribs)Edit filter managers, Administrators172,031 edits Saving copy of the {{drugbox}} taken from revid 452630594 of page 5-Androstenediol for the Chem/Drugbox validation project (updated: '').  Latest revision as of 11:08, 12 February 2024 edit Graeme Bartlett (talk | contribs)Administrators249,413 edits drugbank 
Line 1: Line 1:
{{Short description|Chemical compound}}
{{ambox | text = This page contains a copy of the infobox ({{tl|drugbox}}) taken from revid of page ] with values updated to verified values.}}
{{About|androstenediol the hormone|other uses|Androstenediol (disambiguation)}}
{{Distinguish|androstanedione|androstanediol|androstenedione|androstadienol}}
{{Drugbox {{Drugbox
⚫ | verifiedrevid = 477224050
| Watchedfields = changed
⚫ | IUPAC_name = (3''S'',8''R'',9''S'',10''R'',13''S'',14''S'',17''S'')-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1''H''-cyclopentaphenanthrene-3,17-diol
⚫ | verifiedrevid = 443354154
| image = Androstendiol.svg
⚫ | IUPAC_name = (3''S'',8''R'',9''S'',10''R'',13''S'',14''S'',17''S'')-10,13-Dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1''H''-cyclopentaphenanthrene-3,17-diol
| width = 225px
| image = 5-Androstenediol.png
| image2 = 5-Androstenediol3D.png | image2 = Androstenediol molecule ball.png
| width2 = 235px


<!--Clinical data--> <!--Clinical data-->
| tradename = | tradename =
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X --> | pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B / C / D / X --> | pregnancy_US = <!-- A / B / C / D / X -->
| pregnancy_category = | pregnancy_category =
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 --> | legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII --> | legal_CA = <!-- / Schedule I, II, III, IV, V, VI, VII, VIII -->
| legal_UK = <!-- GSL / P / POM / CD / Class A, B, C --> | legal_UK = <!-- GSL / P / POM / CD / Class A, B, C -->
| legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V --> | legal_US = <!-- OTC / Rx-only / Schedule I, II, III, IV, V -->
| legal_status = | legal_status =
| routes_of_administration = | routes_of_administration = ]
| class = ]; ]


<!--Pharmacokinetic data--> <!--Pharmacokinetic data-->
| bioavailability = | bioavailability =
| protein_bound = | protein_bound =
| metabolism = | metabolism =
| elimination_half-life = | elimination_half-life =
| excretion = | excretion =


<!--Identifiers--> <!--Identifiers-->
| CASNo_Ref = {{cascite|correct|CAS}} | CAS_number_Ref = {{cascite|correct|CAS}}
| CAS_number = 521-17-5 | CAS_number = 521-17-5
| ATC_prefix = | CAS_supplemental =
| ATC_suffix = | ATC_prefix =
| ATC_suffix =
| PubChem = 10634 | PubChem = 10634
| DrugBank_Ref = {{drugbankcite|correct|drugbank}} | DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = | DrugBank = DB01524
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}} | ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10188 | ChemSpiderID = 10188
| UNII_Ref = {{fdacite|correct|FDA}} | UNII_Ref = {{fdacite|correct|FDA}}
| UNII = 95PS51EMXY | UNII = 95PS51EMXY
| KEGG = C04295
| ChEBI_Ref = {{ebicite|correct|EBI}} | ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 2710 | ChEBI = 2710
| ChEMBL_Ref = {{ebicite|correct|EBI}} | ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 440283 | ChEMBL = 440283
| synonyms = A5; Δ<sup>5</sup>-Diol; Androstenediol; Androst-5-ene-3β,17β-diol; Hermaphrodiol; HE2100


<!--Chemical data--> <!--Chemical data-->
| C=19 | H=30 | O=2 | C=19 | H=30 | O=2
⚫ | SMILES = O4C/C3=C/C1(CC2((O)CC12)C)3(C)CC4
| molecular_weight = 290.44
⚫ | smiles = O4C/C3=C/C1(CC2((O)CC12)C)3(C)CC4
| InChI = 1/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1
| InChIKey = QADHLRWLCPCEKT-LOVVWNRFBV
| StdInChI_Ref = {{stdinchicite|correct|chemspider}} | StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1 | StdInChI = 1S/C19H30O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h3,13-17,20-21H,4-11H2,1-2H3/t13-,14-,15-,16-,17-,18-,19-/m0/s1
Line 54: Line 58:
| StdInChIKey = QADHLRWLCPCEKT-LOVVWNRFSA-N | StdInChIKey = QADHLRWLCPCEKT-LOVVWNRFSA-N
}} }}

'''Androstenediol''', or '''5-androstenediol''' (abbreviated as '''A5''' or '''Δ<sup>5</sup>-diol'''), also known as '''androst-5-ene-3β,17β-diol''', is an ] weak ] and ] ] and ] in the ] of ] from ] (DHEA). It is closely related to ] (androst-4-ene-3,17-dione).

==Biological activity==
Androstenediol is a direct ] of the most abundant ] produced by the human ], DHEA. It is less ]ic than the related compound, ], and has been found to stimulate the ]. When administered to ]s, androstenediol, '']'', has approximately 1.4% of the ]icity of DHEA, 0.54% of the androgenicity of ], and 0.21% of the androgenicity of testosterone.<ref>{{cite book | vauthors = Coffey DS | date = 1988 | chapter = Androgen action and the sex accessory tissues | veditors = Knobil E, Neill J | title = The Physiology of Reproduction. | publisher = Raven Press | location = New York | pages = 1081–1119 }}</ref>

Androstenediol possesses potent ]ic activity, similarly to DHEA and ].<ref name="HackenbergTurgetto1993">{{cite journal | vauthors = Hackenberg R, Turgetto I, Filmer A, Schulz KD | title = Estrogen and androgen receptor mediated stimulation and inhibition of proliferation by androst-5-ene-3 beta,17 beta-diol in human mammary cancer cells | journal = The Journal of Steroid Biochemistry and Molecular Biology | volume = 46 | issue = 5 | pages = 597–603 | date = November 1993 | pmid = 8240982 | doi = 10.1016/0960-0760(93)90187-2 | s2cid = 54256515 }}</ref> It has approximately 6% and 17% of the ] of estradiol at the ] and ], respectively.<ref name="pmid9048584">{{cite journal | vauthors = Kuiper GG, Carlsson B, Grandien K, Enmark E, Häggblad J, Nilsson S, Gustafsson JA | title = Comparison of the ligand binding specificity and transcript tissue distribution of estrogen receptors alpha and beta | journal = Endocrinology | volume = 138 | issue = 3 | pages = 863–870 | date = March 1997 | pmid = 9048584 | doi = 10.1210/endo.138.3.4979 | doi-access = free }}</ref> Although androstenediol has far lower affinity for the ERs compared to the major estrogen ], it circulates at approximately 100-fold higher concentrations, and so is thought may play a significant role as an estrogen in the body.<ref name="Bradbury2007">{{cite book| vauthors = Bradbury R |title=Cancer|url=https://books.google.com/books?id=fdtDAAAAQBAJ&pg=PA43|date=30 January 2007|publisher=Springer Science & Business Media|isbn=978-3-540-33120-9|pages=43–}}</ref>

{{Affinities of estrogen receptor ligands for the ERα and ERβ}}

==Chemistry==
{{See also|List of androgens/anabolic steroids#Testosterone derivatives|List of androgen esters#Esters of other natural AAS}}

Androstenediol, also known as androst-5-ene-3β,17β-diol, is a ] ] ].<ref name="Elks2014">{{cite book| vauthors = Elks J |title=The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies|url=https://books.google.com/books?id=0vXTBwAAQBAJ&pg=PA86|date=14 November 2014|publisher=Springer|isbn=978-1-4757-2085-3|pages=86–}}</ref> It is closely related structurally to ] (A4; androst-4-ene-3,17-dione), ] (DHEA; androst-5-en-3β-ol-17-one), and ] (androst-4-en-17β-ol-3-one), as well as to ] (5α-androstane-3β,17β-diol).<ref name="Elks2014" />

]s and ]s of androstenediol, such as the ] ] (17α-methylandrostenediol) and ] (17α-ethynylandrostenediol) as well as the naturally occurring ] derivative ] (19-nor-5-androstenediol), have been ] and studied. Methandriol and its ]s are ]s and ]s while ethinylandrostenediol is an estrogen.

==Research==

===Radiation countermeasure===
Androstenediol has been investigated for use as a radiation countermeasure. Its value as a radiation countermeasure is based mainly on its stimulation of production of ]s and ]s.<ref name="IJI" /> Its potential use as a ] countermeasure was developed by the ] (AFRRI) and subsequently studied by AFRRI and Hollis-Eden Pharmaceuticals under the proposed brand name Neumune for the treatment of ].<ref name="IJI">{{cite journal | vauthors = Whitnall MH, Elliott TB, Harding RA, Inal CE, Landauer MR, Wilhelmsen CL, McKinney L, Miner VL, Jackson WE 3rd, Loria RM, Ledney GD, Seed TM | year = 2000 | title = Androstenediol stimulates myelopoiesis and enhances resistance to infection in gamma-irradiated mice | journal = Int. J. Immunopharmacol. | volume = 22 | issue = 1 | pages = 1–14 | pmid = 10684984 | doi=10.1016/s0192-0561(99)00059-4}}</ref><ref>{{cite journal | vauthors = Grace MB, Singh VK, Rhee JG, Jackson WE 3rd, Kao TC, Whitnall MH | year = 2012 | title = 5-AED enhances survival of irradiated mice in a G-CSF-dependent manner, stimulates innate immune cell function, reduces radiation-induced DNA damage and induces genes that modulate cell cycle progression and apoptosis | journal = J. Radiat. Res. | volume = 53 | issue = 6 | pages = 840–853 | pmid = 22843381 | doi = 10.1093/jrr/rrs060 | pmc=3483857}}</ref>

The ]s with ]s were successful. According to the Hollis-Eden report, only 12.5% of the 40 Neumune-treated animals died versus 32.5% in the ] group.<ref>, February 26, 2007.</ref>

Hollis-Eden had applied for a contract from the U.S. Government under the BioShield Request for Proposals (RFP) for radiation countermeasures. After being encouraged for 2.5 years that Neumune was in the competitive range, on March 9, 2007, the RFP was canceled by ]. According to HHS, "the product was no longer in the competitive range".<ref>, by Val Brickates Kennedy and Angela Moore, March 8, 2007</ref><ref> {{webarchive|url=https://archive.today/20070912210559/http://new.quote.com/stocks/story.action?id=DTM068x6797 |date=2007-09-12 }}, March 9, 2007</ref> No further explanation was given. As a result, Hollis-Eden has now withdrawn from the radiation countermeasure field.

==Additional images==
], with androstenediol at bottom left.]]
{{Clear}}

==References==
{{Reflist|30em}}


{{Endogenous steroids}}
{{Navboxes
| title = ]
| titlestyle = background:#ccccff
| list1 =
{{Androgen receptor modulators}}
{{Estrogen receptor modulators}}
{{Xenobiotic-sensing receptor modulators}}
}}

]
]
]
]
]